Normalized administered atezolizumab dose and clinical outcomes in advanced solid tumors: an exploratory analysis of the phase I PCD4989g study

Immuno-Oncology and Technology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles